Kendall Law Group Investigating IMS Health Inc. Takeover for Shareholders
Business Wire
Nov 06, 2009
Kendall Law Group, founded by a former federal judge, began an
investigation on behalf of IMS Health Inc. (NYSE: RX) shareholders. The
investigation concerns possible breaches of fiduciary duty by the Board
of Directors in connection with the proposed acquisition by private
equity firm Texas Pacific Group and the CPP Investment Board of Toronto.
The transaction is valued at approximately $4 billion, including the
assumption of debt.
According to the agreement, IMS shareholders will receive $22 in cash
for each share owned, which is an almost 31% premium based on the
closing price of IMS on November 4, 2009. Former federal judge Joe
Kendall said, “The investigation concerns whether the consideration to
be paid to shareholders is grossly unfair, inadequate, and substantially
below the fair or inherent value of IMS and whether the directors and
special committee members may have breached their fiduciary duties by
not acting in the shareholders’ best interests in connection with the
sale process.”
If you are a current holder of IMS stock and would like additional
information concerning this proposed transaction, including your
shareholder rights, contact Hamilton Lindley at 877-744-3728 or by email
at hlindley@kendalllawgroup.com.
Kendall Law Group has substantial experience representing investors in
mergers and acquisitions nationwide. Lawyers at the firm include a
former United States Attorney, a former Dallas state and federal judge,
and experienced securities lawyers.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
